Quantamental Technologies’s Neurocrine Biosciences NBIX Stock Holding History

Quantamental Technologies’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$208K	Buy	+1,846	New	+$194K	0.2%	210
2023 Q2	–	Sell	-2,261	Closed	-$229K	–	588
2023 Q1	$229K	Buy	+2,261	New	+$235K	0.12%	311
2022 Q4	–	Sell	-3,887	Closed	-$413K	–	593
2022 Q3	$413K	Buy	+3,887	New	+$394K	0.16%	230
2022 Q1	–	Sell	-3,408	Closed	-$290K	–	501
2021 Q4	$290K	Buy	+3,408	New	+$313K	0.15%	262
2020 Q1	–	Sell	-5,045	Closed	-$542K	–	301
2019 Q4	$542K	Buy	5,045 +1,808	+56%	+$189K	0.28%	108
2019 Q3	$292K	Buy	3,237 +787	+32%	+$73.5K	0.1%	354
2019 Q2	$207K	Buy	2,450 +292	+14%	+$24K	0.08%	427
2019 Q1	$190K	Buy	+2,158	New	+$180K	0.09%	392

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quantamental Technologies's NBIX Position: Q3 2023 in Review

Quantamental Technologies opened a new position in Neurocrine Biosciences (NBIX) in Q3 2023: 1,846 shares worth $208K. The stake represents 0.2% of the portfolio and ranks #210 among its holdings. This is a return to the name: Quantamental Technologies previously reported a position in NBIX as recently as Q1 2023.

Quantamental Technologies first reported a position in NBIX in Q1 2019 and has held it in 8 quarters since. The position peaked at $542K in Q4 2019. 512 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

Quantamental Technologies held 1,846 shares of Neurocrine Biosciences worth $208K as of Q3 2023.
Neurocrine Biosciences was a new Quantamental Technologies position in Q3 2023.
Neurocrine Biosciences made up 0.2% of Quantamental Technologies's portfolio in Q3 2023, its #210 holding.
Quantamental Technologies first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 8 quarters since.
Quantamental Technologies's Neurocrine Biosciences position peaked at $542K in Q4 2019.
512 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on Quantamental Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.